Stéphanie Héon

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino et al. · Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacology, Cancer Pharmacology +15

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib

Stéphanie Héon, Beow Y. Yeap, Gregory Joseph Britt et al. · Clinical Cancer Research · 2010 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman et al. · Clinical Cancer Research · 2012 · 179 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Delay of chemotherapy through use of post-progression erlotinib in patients with <i>EGFR</i>-mutant lung cancer.

Geoffrey R. Oxnard, Peter Lo, David M. Jackman et al. · Journal of Clinical Oncology · 2012 · 34 citations

Medicine, Oncology, Pharmacology +15

Dexrazoxane does not protect against doxorubicin-induced damage in young rats

Stéphanie Héon, Martin Bernier, Nicolas Servant et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2003 · 27 citations

Medicine, Cardiology, Pharmacology +17